SYSTEMIC SCLEROSIS

This large, late-stage study is testing whether a new oral medication called nerandomilast can help control systemic sclerosis (scleroderma), a rare autoimmune disease that causes skin thickening and can damage internal organs. About 448 adults with early-stage scleroderma will b…

This study is testing whether nemolizumab can reduce skin thickening and improve overall health in adults with systemic sclerosis, a rare autoimmune disease that causes skin and organ scarring. About 162 participants will receive either the drug or a placebo for 52 weeks to find …

This study is testing whether a new type of cell therapy, called CAR T-cells, is better and safer than current standard treatments for people with active systemic sclerosis (scleroderma) that affects the lungs. It will involve about 92 adults whose disease has not responded well …

This study is testing a new type of cell therapy called CD19 UCAR-T in people with various autoimmune diseases that haven't responded well to standard treatments. The main goals are to see if the treatment is safe and if it can help control the diseases. It will involve a small g…

This study aims to find the best way to share research results with people who have scleroderma, a rare autoimmune disease. Researchers will compare whether patients prefer receiving information through infographics or plain-language summaries. About 128 participants will rate th…

This study aims to understand how often and what types of sleep breathing problems occur in people with systemic sclerosis (scleroderma). Researchers will monitor the sleep of 30 adult patients overnight to gather detailed information. The goal is to fill a knowledge gap and see …

This study aims to understand if a substance in the blood called catestatin is linked to heart and blood vessel problems in people with systemic sclerosis (scleroderma). Researchers will measure catestatin levels in 70 patients and compare them to healthy people, looking for conn…